pancreatic cancer pancreatic ductal adenocarcinoma
Conditions
Interventions
Investigational treatment consists of oral micellar curcumin (Espera C®).
Patients will receive 2dd2 capsules (18 mg micellar curcumin/capsule) for a
period of 6 weeks. Patients will undergo blood s
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Age between 18 and 65 years. * Diagnosed with stable pancreatic cancer after standard of care treatment (defined as no detectable disease recurrence or disease progression on CT imaging within 6 weeks after completing standard of care treatment. * Completed standard of care treatment. * Bilirubin
Exclusion criteria
Exclusion criteria: * Previous malignancy (excluding non-melanoma skin cancer), unless no evidence of disease and diagnosed more than 2 years before diagnosis of pancreatic cancer. * Pregnancy. * Unable to draw blood for study purposes. * Serious concomitant systemic disorders that would compromise the safety of the participant or their ability to complete the study, at the discretion of the investigator. * Surgery, or other procedures (other than the pancreatic surgery) that have altered the gastrointestinal integrity which might influence uptake op Espera C®.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine whether micellar curcumin (Espera C®) is able to skew the T-cell subsets of PDAC patients with stable disease after standard of care treatment. Additionally, we will determine whether curcumin*s effects on the immune status is reflected by improvement in the SIII and the differences in immunology-related gene expression and cell types between PDAC patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine whether curcumin*s effects on the immune status is reflected by improvement in the SIII and the differences in immunology-related gene expression and cell types between PDAC patients. | — |
Countries
Netherlands
Outcome results
None listed